Organization
University of Perugia, Ospedale Santa Maria della Misericordia
1 abstract
Abstract
Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design.Org: Melanoma Institute Australia, University Hospital (UKSH), Campus Kiel, Department of Dermatology, Kiel, Germany, University of Perugia, Ospedale Santa Maria della Misericordia, European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, European Organization for Research and Treatment of Cancer (EORTC), Headquarters,